AstraZeneca's shares fell nearly 9% after its experimental heart drug, Wainua, failed to meet the primary goal in a late-stage trial. The drug aimed to reduce deaths and heart-related emergencies over 140 weeks for patients with a rare heart condition called transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The failure marks a significant setback for the British drugmaker, with shares hitting their worst day since March 2020. Investors will be watching closely for AstraZeneca's next steps following this trial result.
AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present v...
AstraZeneca and Ionis Pharmaceuticals saw their shares drop after their jointly developed heart disease drug, Wainua, failed a late-stage trial. The drug, designed as a monthly gene silencer injection, did not show a statistically significant benefit...
AstraZeneca's shares fell 9.55%, wiping £19 billion off its value, after its Wainua drug failed a major Phase III trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial did not meet its primary goal of reducing cardiovascular de...
AstraZeneca's Phase III trial for its drug Wainua failed to meet its primary endpoint, causing a 9% drop in its shares and pulling the FTSE 100 into negative territory. The trial aimed to treat a rare heart disease but showed no significant benefit o...
New research from Spherix Global Insights reveals that despite advances in lupus treatment, including increased use of biologics and new therapies, many patients with systemic lupus erythematosus (SLE) continue to experience persistent symptoms, freq...
